Evidence map›Paper›PMID 24419386›Full record

ArticleActa crystallographica. Section D, Biological crystallography2014

Ligand placement based on prior structures: the guided ligand-replacement method.

Herbert E Klei, Nigel W Moriarty, Nathaniel Echols, Thomas C Terwilliger, Eric T Baldwin, Matt Pokross, Shana Posy, Paul D Adams

Abstract read
In one paragraph

Article in Acta crystallographica. Section D, Biological crystallography, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Models of protein-ligand crystal structures: trust, but verify.Journal of computer-aided molecular design · 2015
    Article
  8. The solvent component of macromolecular crystals.Acta crystallographica. Section D, Biological crystallography · 2015
    Review
  9. Article
  10. Automating crystallographic structure solution and refinement of protein-ligand complexes.Acta crystallographica. Section D, Biological crystallography · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Herbert E KleiPhysical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Nigel W MoriartyPhysical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Nathaniel EcholsPhysical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Thomas C TerwilligerLos Alamos National Laboratory, Los Alamos, NM 87545-0001, USA.
Eric T BaldwinResearch and Development, Bristol-Myers Squibb, Princeton, NJ 08543-4000, USA.
Matt PokrossResearch and Development, Bristol-Myers Squibb, Princeton, NJ 08543-4000, USA.
Shana PosyResearch and Development, Bristol-Myers Squibb, Princeton, NJ 08543-4000, USA.
Paul D AdamsPhysical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.

Funding

PROJECT 5 - DUKE - STRUCTURE VALIDATION AND IMPROVEMENT FOR PROTEINS AND N. ACIDSP01GM063210 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI ADAMS, PAUL DAVID · 2001 to 2021
$33.5M
NIGMS NIH HHS 1P01 GM063210NIGMS NIH HHS P01 GM063210
6 · The paper itself

Abstract

The process of iterative structure-based drug design involves the X-ray crystal structure determination of upwards of 100 ligands with the same general scaffold (i.e. chemotype) complexed with very similar, if not identical, protein targets. In conjunction with insights from computational models and assays, this collection of crystal structures is analyzed to improve potency, to achieve better selectivity and to reduce liabilities such as absorption, distribution, metabolism, excretion and toxicology. Current methods for modeling ligands into electron-density maps typically do not utilize information on how similar ligands bound in related structures. Even if the electron density is of sufficient quality and resolution to allow de novo placement, the process can take considerable time as the size, complexity and torsional degrees of freedom of the ligands increase. A new module, Guided Ligand Replacement (GLR), was developed in Phenix to increase the ease and success rate of ligand placement when prior protein-ligand complexes are available. At the heart of GLR is an algorithm based on graph theory that associates atoms in the target ligand with analogous atoms in the reference ligand. Based on this correspondence, a set of coordinates is generated for the target ligand. GLR is especially useful in two situations: (i) modeling a series of large, flexible, complicated or macrocyclic ligands in successive structures and (ii) modeling ligands as part of a refinement pipeline that can automatically select a reference structure. Even in those cases for which no reference structure is available, if there are multiple copies of the bound ligand per asymmetric unit GLR offers an efficient way to complete the model after the first ligand has been placed. In all of these applications, GLR leverages prior knowledge from earlier structures to facilitate ligand placement in the current structure.

Indexed as

Drug DesignCrystallography, X-RayHIV-1HIV ProteaseHumansLigandsModels, Molecularp38 Mitogen-Activated Protein KinasesProtein BindingHIV ProteaseLigandsp38 Mitogen-Activated Protein KinasesGLRguided ligand-replacement methodligand placement

Identifiers

PMID24419386
PMCPMC3919265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.